20 May 2020
The world may see its first novel coronavirus vaccine deployed between March and June next year based on the most optimistic estimate, a leading COVID-19 expert in Shanghai said on May 15.
If not, chances are that a vaccine will become available at the end of next year or the beginning of 2022, said Zhang Wenhong, leader of the Shanghai team of experts in the clinical treatment of novel coronavirus pneumonia cases.
There are 108 novel coronavirus vaccines undergoing research and development around the world, according to a World Health Organization list, with some having entered clinical trials.
A senior Chinese scientist said on Friday that the country had five vaccines-one vector and four inactivated-that had entered the first two phases of clinical trials in China. They are set to complete their phase two trials in July.
In the United States, some vaccines have proceeded to phase three clinical trials.
But the progress of work on vaccines would generally depend on whether the novel coronavirus stayed around for the long term or basically disappeared, just like the viruses responsible for severe acute respiratory syndrome and Middle East respiratory syndrome, said Zhang, who is also director of the department of infectious diseases at Shanghai Huashan Hospital Affiliated with Fudan University.
If the virus disappears, almost all the R& D programs on vaccines will probably be suspended, he said during a discussion hosted by Shanghai-based conglomerate Fosun International.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024